This article was originally published in The Tan Sheet
Revenues during the firm's second quarter grew 17.8 % to $19.5 mil., fueled by the strong performance of new the products which more than offset a decline from the discontinuation of Ester-C, the Chatsworth, Calif.-based firm says. The nutritional products company adds it is well-positioned to enter the international marketplace, and is benefiting from the diversification of its business through the recent acquisition of MRI (1"The Tan Sheet" June 18, 2007, p. 7). Operating income jumped 172.9% during the quarter to $737,000 while net income was $4.2 mil. compared to $100,000 in the year-ago period, the firm notes...
You may also be interested in...
Dietary supplement manufacturer Natrol expands its sports nutrition product offerings with its $8 million cash acquisition of Medical Research Institute
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.
The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.